https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-01-12 09:17:252024-04-01 17:43:03NUOVE INDICAZIONI RIMBORSATE DI TRASTUZUMAB DERUXTECAN: G.U. del 20 dicembre 2023
https://www.aigom.it/wp-content/uploads/2023/12/MONARCH-3.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-12-21 10:43:542023-12-21 10:44:14MONARCH 3: Risultati dell’analisi finale della sopravvivenza globale presentati al San Antonio Breast Cancer Symposium (SABCS) il 6 dicembre 2023.
https://www.aigom.it/wp-content/uploads/2023/12/MAINTAIN-TRIAL.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-12-04 10:20:012023-12-04 10:21:34Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
https://www.aigom.it/wp-content/uploads/2023/11/open-pts.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-11-28 09:43:402023-11-28 09:43:40Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
https://www.aigom.it/wp-content/uploads/2023/11/DROBNI.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-11-21 14:04:232023-11-21 14:10:14Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-05-29 07:19:012023-10-25 13:39:36Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-04-17 10:13:542023-04-17 10:20:09US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
